Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients

Main Article Content

LF Eichenfield
Departments of Dermatology and Pediatrics; University of California, San Diego School of Medicine and Rady Children?s Hospital, San Diego, CA

B Elewski
University of Alabama at Birmingham School of Medicine, Birmingham, AL

JL Sugarman
University of California, San Francisco, CA

T Rosen
Baylor College of Medicine, Houston, TX

A Gupta
Mediprobe Research Inc., London, ON and University of Toronto, Toronto, ON

R Pillai
Bausch Health US, LLC*, Petaluma, CA *Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC.

T Lin
Ortho Dermatologics*, Bridgewater, NJ *Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC.

Keywords

Efinaconazole, Onychomycosis

Abstract

Abstract not available.

References

1. Gupta AK, et al. Pediatr Dermatol. 2018;35(5):552-559.
2. Rodriguez-Pazos L, et al. Mycoses. 2011;54(5):450-453.
3. Eichenfield LF, Friedlander SF. J Drugs Dermatol. 2017;16(2):105-109.
4. Prescribing Information. JUBLIA® (efinaconazole) topical solution, 10%. Ortho Dermatologics.

Article Sidebar

Poster PDF
Published
Jan 28, 2020

Article Details

How to Cite
[1]
Eichenfield, L., Elewski, B., Sugarman, J., Rosen, T., Gupta, A., Pillai, R. and Lin, T. 2020. Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients. SKIN The Journal of Cutaneous Medicine. 4, 1 (Jan. 2020), S22.
Issue
Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Section
Nail Unit Disorders
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)